U.S. Household Products Stock News

NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Is It Time To Reassess Alkermes (ALKS) After Strong Recent Share Price Gains

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...
NYSE:TRV
NYSE:TRVInsurance

A Look At Travelers Companies (TRV) Valuation Following Recent Share Price Moves

Why Travelers Companies Stock Is On Investors’ Radar Travelers Companies (TRV) is drawing fresh attention after recent trading left the stock around $298.94, with returns ranging from a small 1 day decline to a modest gain over the past month. See our latest analysis for Travelers Companies. At around $298.94, the stock has seen a recent 1 day share price return of -0.88% and a 30 day share price return of 1.32%. The 1 year total shareholder return of 12.13% and 5 year total shareholder...
NYSE:MMS
NYSE:MMSProfessional Services

The Bull Case For Maximus (MMS) Could Change Following AI-Driven Margins And A New Buyback Plan

In early May 2026, Maximus reported second-quarter results showing sales of US$1,305.97 million versus US$1,361.79 million a year earlier, while net income edged up to US$98.06 million and the board authorized a new US$400 million share repurchase program after completing US$859.41 million of prior buybacks. The company’s ability to grow earnings per share despite lower revenue, supported by AI-driven efficiency gains and renewed buyback capacity, highlights a business model increasingly...
NYSE:HRB
NYSE:HRBConsumer Services

Why H&R Block (HRB) Is Up 14.4% After EPS Jump And Dividend Hold - And What's Next

H&R Block reported past third-quarter fiscal 2026 results showing revenue of US$2,398.11 million and net income of US$847.9 million, alongside a quarterly dividend of US$0.42 per share payable in July. The strong increase in earnings per share, helped by a one-time tax benefit and share repurchases, underpins the company’s decision to maintain its long-running dividend streak. With H&R Block’s recent earnings strength and higher full-year revenue outlook, we’ll now examine how this updates...
NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

How Investors May Respond To SoFi Technologies (SOFI) Record Profitability But Unchanged 2026 Outlook

In the first quarter of 2026, SoFi Technologies, Inc. reported net income of US$166.73 million, up from US$71.12 million a year earlier, with basic earnings per share from continuing operations rising to US$0.13. Alongside record revenue, member growth and new products like SoFi Plus and business banking, SoFi’s decision to keep full-year guidance unchanged drew close attention to how management is balancing growth investments and profitability. We’ll now examine how SoFi’s record...
NasdaqGS:PRVA
NasdaqGS:PRVAHealthcare

Is Privia Health Group (PRVA) Attractive After Recent Volatility And Conflicting Valuation Signals?

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Astera Labs (ALAB) Valuation Check After Record Q1 2026 Results And AI Switch Expansion

Astera Labs (ALAB) has drawn fresh attention after reporting record Q1 2026 results, with sales nearly doubling year over year to US$308.36 million, alongside higher net income and detailed guidance for Q2. See our latest analysis for Astera Labs. Astera Labs’ share price has been volatile around the Q1 release, with a 1-day share price decline of 8.54%, a 30-day share price return of 64.43%, and a 1-year total shareholder return of 173.10%. This suggests momentum has been strong despite...
NYSE:MSI
NYSE:MSICommunications

Motorola Solutions (MSI) Earnings Margin Expansion Reinforces Bullish Software And Services Narrative

Motorola Solutions (MSI) closed out FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$3.90, supported by net income of US$649 million. Trailing 12 month figures show revenue of US$11.7 billion and basic EPS of US$12.93. Over the past year, revenue has moved from US$10.8 billion to US$11.7 billion and basic EPS has gone from US$9.45 to US$12.93, alongside trailing 12 month net income rising from US$1.6 billion to US$2.2 billion. This sets the backdrop for a profit story...
NYSE:BFAM
NYSE:BFAMConsumer Services

A Look At Bright Horizons (BFAM) Valuation After Q1 2026 Earnings Beat And 7% Revenue Growth

Bright Horizons Family Solutions (BFAM) just reported Q1 2026 results, with revenue up 7% year over year and earnings ahead of Wall Street forecasts, while reaffirming full year revenue and adjusted EPS guidance. See our latest analysis for Bright Horizons Family Solutions. Despite the earnings beat and revenue growth in Q1 2026, Bright Horizons’ recent share price performance has been weak. The 30-day share price return is 17.68% and the year to date share price return is 31.21%, while the 1...
NYSE:IONQ
NYSE:IONQTech

Is It Too Late To Consider IonQ (IONQ) After Its Recent Share Price Surge?

If you are wondering whether IonQ's current share price lines up with its fundamentals, this article walks through the key signals investors often rely on when thinking about value. The stock last closed at US$47.68, with returns of 5.7% over 7 days, 67.4% over 30 days, 1.9% year to date and 49.7% over 1 year. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage has focused on IonQ as a pure play in quantum computing, with attention on...
NYSE:PCG
NYSE:PCGElectric Utilities

PG&E (PCG) Valuation Check After Recent Share Price Weakness

PG&E stock after recent performance shifts PG&E (PCG) has seen recent share price pressure, with the stock showing a 0.1% decline over the past day and a larger pullback over the past week, month, and past three months. See our latest analysis for PG&E. That short term weakness adds to a 1 month share price return of an 8.1% decline and a year to date share price return of a 0.5% decline, while the 5 year total shareholder return of 54.5% shows earlier momentum that has cooled in recent...
NYSE:RHP
NYSE:RHPHotel and Resort REITs

A Look At Ryman Hospitality Properties (RHP) Valuation After Strong First Quarter Earnings And Dividend Declaration

Ryman Hospitality Properties (RHP) has drawn fresh attention after reporting first quarter 2026 results, with sales of US$223.76 million and revenue of US$664.57 million, alongside net income of US$70.48 million. See our latest analysis for Ryman Hospitality Properties. The first quarter earnings and the recently declared US$1.20 second quarter dividend have come alongside a 30 day share price return of 17.63% and a 1 year total shareholder return of 19.82%. This suggests that momentum has...
NasdaqCM:VRRM
NasdaqCM:VRRMProfessional Services

Is It Time To Reconsider Verra Mobility (VRRM) After A 39.7% One Year Share Price Fall

Wondering whether Verra Mobility stock is starting to look appealing at its current price, especially after a tough run? This article focuses squarely on what that price might really imply about value. The stock last closed at US$14.63 and has returned 0.5% over 30 days, yet year to date it is down 34.5% and the 1 year return is a 39.7% decline, which can change how investors think about both risk and opportunity. Recent coverage has focused on how the stock's weaker 1 year and 3 year...
NYSE:CLF
NYSE:CLFMetals and Mining

Cleveland Cliffs (CLF) Valuation Check After Q1 Strength Momentum Shift And Rising Short Interest

Why Cleveland-Cliffs stock is drawing fresh attention A recent mix of a strong first quarter report, an 80 day moving average crossover and rising short interest has put Cleveland-Cliffs (CLF) back on investors’ radar as trading activity picks up. See our latest analysis for Cleveland-Cliffs. That technical upswing and upbeat first quarter arrive after a mixed stretch, with a 22.27% 1 month share price return and a 48.95% 1 year total shareholder return set against weaker longer term total...
NasdaqCM:SERV
NasdaqCM:SERVHospitality

Serve Robotics (SERV) Posts US$34 Million Quarterly Loss Challenging Bullish Growth Narratives

Serve Robotics (SERV) has posted FY 2025 results that highlight a small but growing top line alongside sizable losses, with Q4 revenue at about US$0.9 million and a quarterly net loss of roughly US$34.3 million, or EPS of US$0.46 loss, while trailing 12 month revenue sits at roughly US$2.7 million against a net loss of about US$101.4 million and EPS of US$1.63 loss. Over recent quarters the company has seen revenue move from around US$0.18 million in Q4 FY 2024 to US$0.88 million in Q4 FY...
NYSE:TAP
NYSE:TAPBeverage

A Look At Molson Coors (TAP) Valuation After Its Latest Quarterly Earnings Update

Molson Coors Beverage (TAP) stock is reacting to fresh quarterly results, with first quarter sales of US$2,717.9 million and net income of US$151.3 million, along with a regular US$0.48 per share dividend declaration. See our latest analysis for Molson Coors Beverage. The first quarter update has come against a weak backdrop for the stock, with a 90 day share price return of a 16.67% decline and a 1 year total shareholder return of a 17.34% loss, so recent momentum has been fading despite...
NasdaqCM:AKBA
NasdaqCM:AKBABiotechs

Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...
NYSE:MUX
NYSE:MUXMetals and Mining

McEwen (MUX) Is Up 7.8% After Q1 Profit, 2030 Output Target Update Has The Bull Case Changed?

Earlier this week, McEwen Inc. reported Q1 2026 results showing net income of US$33.4 million and revenue growth of very large versus a year earlier, reaffirmed its 2026 production guidance, and detailed progress on projects across North and South America. The company also advanced its long-term growth plan by activating a 50-50 joint venture on the New Pass gold property in Nevada, completing the Golden Lake Resources acquisition near its Gold Bar complex, and outlining a path to...
NasdaqGS:JBLU
NasdaqGS:JBLUAirlines

A Look At JetBlue Airways (JBLU) Valuation As Card Refresh And Fort Lauderdale Expansion Advance

Credit card refresh and Fort Lauderdale build out take center stage JetBlue Airways (JBLU) has put its co branded JetBlue Premier World Elite Mastercard and Fort Lauderdale expansion at the heart of its current push to win and retain travelers after Spirit Airlines’ shutdown. The card now offers larger statement credits, status related tile bonuses and a sizable limited time TrueBlue points offer. Fort Lauderdale is set to see new routes, added frequencies and targeted perks for former Spirit...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

Is GitLab (GTLB) Now Attractive After Sharp Share Price Declines This Year?

If you are wondering whether GitLab at around US$25.92 is priced attractively or not, the key is understanding what the current valuation is actually baking in for the future. The stock has recently been volatile, with a 17.1% return over the last 7 days and 12.0% over the last 30 days, yet it still sits on a year to date return of 28.4% decline and a 1 year return of 47.7% decline. Recent coverage has focused on GitLab as a software platform positioned in a competitive developer tools...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

Why NANO Nuclear Energy (NNE) Is Up 14.2% After AI Data Center Microreactor MOU And What's Next

In early May 2026, Nano Nuclear Energy Inc. announced a non-binding Memorandum of Understanding with Super Micro Computer, Inc. to explore integrating its KRONOS MMR microreactors with Supermicro’s AI server and data center platforms to create on-site nuclear-powered AI infrastructure. This collaboration highlights how pairing microreactors with AI data centers could create self-powered, grid-independent computing hubs aimed at meeting rapidly rising electricity needs from artificial...
NYSE:VRT
NYSE:VRTElectrical

A Look At Vertiv Holdings (VRT) Valuation After Strong Q1 2026 Results And AI Data Center Momentum

Vertiv Holdings Co (VRT) has drawn fresh attention after reporting strong Q1 2026 results, highlighting 23% organic sales growth, a raised full year outlook, and growing exposure to AI data center infrastructure. See our latest analysis for Vertiv Holdings Co. That strong Q1 update sits on top of powerful momentum, with a 30 day share price return of 29.63% and a 90 day gain of 73.85%. The 1 year total shareholder return of 255.57% and very large 3 year total shareholder return signal how...
NYSE:BIO
NYSE:BIOLife Sciences

A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut

Bio-Rad Laboratories (BIO) stock is in focus after Q1 2026 results showed sales of US$592.1 million and a net loss of US$527.1 million, alongside weaker bioprocessing demand and cautious biotech spending. See our latest analysis for Bio-Rad Laboratories. The Q1 2026 net loss and reduced revenue outlook have been followed by a 7 day share price return of 8.14% decline and a year to date share price return of 15.71% decline, while the 1 year total shareholder return of 6.76% suggests longer...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next

Earlier this week, Ardelyx presented new long-term data at the National Kidney Foundation’s Spring Clinical Meetings showing that XPHOZAH (tenapanor) reduced serum phosphate in chronic kidney disease patients on dialysis without causing clinically meaningful changes in other serum electrolytes, nutrition markers, body mass, or blood pressure. This extended safety and efficacy profile for the first-in-class phosphate absorption inhibitor could strengthen XPHOZAH’s clinical positioning as an...